Avivagen Announces U.S. Product Launch of Vivamune for Cats

Accesswire

OTTAWA, ONTARIO, August 20, 2013 - Avivagen Inc. (VIV.V), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces its United States launch of Vivamune(TM) Health Chews for cats.

Avivagen is pleased to announce the launch of its latest product - Vivamune(TM) Health Chews for cats. Now U.S. pet parents have direct access to this exciting new feline health supplement. The proprietary ingredients in Vivamune(TM) Health Chews have been shown to act on the immune system and may thereby support healthy skin, coat and gut and help to maintain normal mobility. This science-based and highly-palatable natural chew is intended to help cats lead long and healthy lives.

U.S. pet parents can order Vivamune(TM) Health Chews for their cats online at www.vivamunehealth.com.

Dave Hankinson, Executive Director of Avivagen, commented on this important milestone, "For some time our customers have asked us when Avivagen was going to introduce a product for cats comparable to our Vivamune(TM) product for dogs. After putting in the necessary time and effort to develop a formulation suitable for cats, it is exciting to introduce our product for this important companion animal species, further broadening access to Avivagen's health discoveries."

Cameron Groome, CEO and President of Avivagen, remarked, "The launch of Vivamune(TM) Health Chews for cats is an important milestone for Avivagen: It is gratifying to bring forward a further product that meets our customers' needs and at the same time provides a further source of revenues for Avivagen. In the coming quarters we will continue to drive sales of our three commercial products, Vivamune(TM) Health Chews, Oximunol(TM) Chewable Tablets and OxC-beta for livestock."

About Avivagen Inc.

Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol "VIV". The Company's goal is to develop and deliver scientifically-proven solutions that can truly benefit companion and production animals by employing natural mechanisms for maintaining good health. Avivagen's targeted markets include Pet Wellness and Livestock Productivity.

The company has sites located in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island.

More information can be found at www.avivagen.com.

About OxC-beta

Avivagen's proprietary and patent-protected technology is based on its discoveries concerning carotenoid antioxidants. The novel natural compounds discovered by Avivagen support the body's own systems to maintain and enhance health, particularly by supporting immune function. Avivagen's commercial-stage application of its technology is Fully-Oxidized beta-Carotene (OxC-beta).

OxC-beta compounds occur naturally as carotenoid oxidation products in vegetation, but in minute amounts. They have been developed to support the health of companion animals and for use in the global food animal market.

Research results indicate OxC-beta supports innate immune function, which can help maintain good health. In pets, OxC-beta supports overall vitality and energy, mobility and joint function, skin, coat and gut. Results observed in food animals have included healthier growth, better utilization of feed and decreased mortality. In food animals, it is intended that use of OxC-beta avoids the feeding of antibiotics.

The commercial products of Avivagen are Oximunol(TM) Chewables, OxC-beta for livestock and Vivamune(TM) Health Chews.

About Vivamune(TM) Health Chews - "For dogs that dig life" and "extraordinary cats"

Vivamune(TM) Health Chews are scientifically-formulated chews for dogs and cats that contain Avivagen's proprietary active ingredients. Vivamune(TM) Health Chews work with a pet's own immune system to maintain overall health and well-being. They are sold in re-sealable packages of 30 chews and are currently available in the United States by ordering on-line at www.vivamunehealth.com.

About Oximunol(TM) Chewables - "Optimized Health in a Chewable Tablet"

Oximunol(TM) Chewables are scientifically-formulated chewable tablets that contain Avivagen's proprietary, patented active ingredient OxC-beta. OxC-beta has been shown to stimulate innate cellular immunity and may thereby help to maintain overall health and well-being. Oximunol(TM) Chewables are available through veterinarians for dogs of all ages in the United States.

About OxC-beta for Livestock

OxC-beta for Livestock is available as a 10% pre-mix sold in 1.0 or 5.0 Kg quantities for parts-per-million addition to animal feeds, in accordance with producer-developed protocols. In prior studies, OxC-beta has been shown to support health and growth in species such as fish, chicken, pigs and cattle. OxC-beta for livestock is currently available for commercial sale in the Kingdom of Thailand.

Forward Looking Statements
This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Avivagen Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

Avivagen Inc.

Cameron Groome

CEO & President

Phone: 613-949-8164

c.groome@avivagen.com

View Comments